Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNPX NASDAQ:INM NASDAQ:RNAZ NASDAQ:SCNI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.48-7.3%$0.81$0.42▼$55.00$5.69M-0.98396,294 shs195,120 shsINMInMed Pharmaceuticals$1.55+3.3%$1.17$0.58▼$4.03$4.97M0.9889,913 shs47,672 shsRNAZTransCode Therapeutics$4.89+0.6%$6.58$3.82▼$20.99$4.61M1.28144,886 shs11,455 shsSCNIScinai Immunotherapeutics$0.27-4.8%$0.48$0.27▼$3.48$1.13M2.05533,884 shs148,544 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex-7.29%-0.08%-41.18%-74.31%-96.14%INMInMed Pharmaceuticals+3.33%+4.03%-9.88%+127.57%-59.95%RNAZTransCode Therapeutics+0.62%-8.60%-21.63%-42.74%-37.23%SCNIScinai Immunotherapeutics-4.83%-19.23%-40.98%-54.71%-88.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.48-7.3%$0.81$0.42▼$55.00$5.69M-0.98396,294 shs195,120 shsINMInMed Pharmaceuticals$1.55+3.3%$1.17$0.58▼$4.03$4.97M0.9889,913 shs47,672 shsRNAZTransCode Therapeutics$4.89+0.6%$6.58$3.82▼$20.99$4.61M1.28144,886 shs11,455 shsSCNIScinai Immunotherapeutics$0.27-4.8%$0.48$0.27▼$3.48$1.13M2.05533,884 shs148,544 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex-7.29%-0.08%-41.18%-74.31%-96.14%INMInMed Pharmaceuticals+3.33%+4.03%-9.88%+127.57%-59.95%RNAZTransCode Therapeutics+0.62%-8.60%-21.63%-42.74%-37.23%SCNIScinai Immunotherapeutics-4.83%-19.23%-40.98%-54.71%-88.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNPXGenprex 1.00SellN/AN/AINMInMed Pharmaceuticals 1.00SellN/AN/ARNAZTransCode Therapeutics 1.00SellN/AN/ASCNIScinai Immunotherapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCNI, GNPX, RNAZ, and INM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026INMInMed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026RNAZTransCode Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SCNIScinai Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNPXGenprexN/AN/AN/AN/A$2.42 per shareN/AINMInMed Pharmaceuticals$4.94M1.04N/AN/A$6.71 per share0.23RNAZTransCode TherapeuticsN/AN/AN/AN/A$11.27 per shareN/ASCNIScinai Immunotherapeutics$1.31M0.82N/AN/A$0.78 per share0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNPXGenprex-$16.23M-$14.14N/AN/AN/AN/A-247.32%-176.73%9/2/2026 (Estimated)INMInMed Pharmaceuticals-$8.16M-$2.89N/AN/AN/A-132.87%-80.85%-68.11%N/ARNAZTransCode Therapeutics-$34.66M-$50.33N/AN/AN/AN/A-875.35%-50.36%8/18/2026 (Estimated)SCNIScinai Immunotherapeutics-$8.31M-$4.63N/AN/AN/AN/AN/AN/A7/7/2026 (Estimated)Latest SCNI, GNPX, RNAZ, and INM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RNAZTransCode TherapeuticsN/A-$21.28N/A-$21.28N/AN/A5/13/2026Q1 2026GNPXGenprexN/A-$0.64N/A-$0.64N/AN/A5/6/2026Q3 2026INMInMed Pharmaceuticals-$94.4436-$0.69+$93.7536-$0.73$1.20 millionN/A4/1/2026Q4 2025SCNIScinai ImmunotherapeuticsN/A$3.80N/A$3.80N/A$0.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGNPXGenprexN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNPXGenprexN/A5.615.61INMInMed PharmaceuticalsN/A3.123.12RNAZTransCode TherapeuticsN/A3.113.11SCNIScinai Immunotherapeutics0.051.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNPXGenprex14.05%INMInMed Pharmaceuticals20.12%RNAZTransCode TherapeuticsN/ASCNIScinai Immunotherapeutics58.41%Insider OwnershipCompanyInsider OwnershipGNPXGenprex0.25%INMInMed Pharmaceuticals0.85%RNAZTransCode Therapeutics0.10%SCNIScinai Immunotherapeutics60.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNPXGenprex2010.93 million10.90 millionNo DataINMInMed Pharmaceuticals103.31 million3.29 millionNot OptionableRNAZTransCode Therapeutics9950,000949,000Not OptionableSCNIScinai Immunotherapeutics203.96 million1.55 millionNot OptionableSCNI, GNPX, RNAZ, and INM HeadlinesRecent News About These CompaniesScinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth InitiativesJune 10, 2026 | prnewswire.comScinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO FacilityMay 20, 2026 | prnewswire.comScinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit EuropeMay 15, 2026 | prnewswire.comScinai Immunotherapeutics Announces $2.61 Million Private Placement FinancingApril 24, 2026 | prnewswire.comScinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 PrioritiesApril 6, 2026 | prnewswire.comScinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm CollaborationApril 1, 2026 | prnewswire.comScinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026March 19, 2026 | prnewswire.comScinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid PriceMarch 16, 2026 | prnewswire.comScinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of ConceptMarch 2, 2026 | prnewswire.comScinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish PlatformFebruary 25, 2026 | prnewswire.comScinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with RecipharmFebruary 17, 2026 | prnewswire.comScinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthILJanuary 7, 2026 | prnewswire.comScinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short InterestJanuary 2, 2026 | defenseworld.netDScinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline AdvancesDecember 2, 2025 | prnewswire.comScinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO CapabilitiesOctober 6, 2025 | prnewswire.comScinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance SheetSeptember 2, 2025 | prnewswire.comScinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TENJuly 29, 2025 | prnewswire.comScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025June 12, 2025 | prnewswire.comScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.June 5, 2025 | prnewswire.comScinai Immunotherapeutics Reports Strong CDMO GrowthJune 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCNI, GNPX, RNAZ, and INM Company DescriptionsGenprex NASDAQ:GNPX$0.48 -0.04 (-7.29%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$0.48 -0.01 (-1.24%) As of 06/24/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.InMed Pharmaceuticals NASDAQ:INM$1.55 +0.05 (+3.33%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$1.55 0.00 (-0.06%) As of 06/24/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.TransCode Therapeutics NASDAQ:RNAZ$4.89 +0.03 (+0.62%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$4.90 +0.02 (+0.31%) As of 06/24/2026 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.Scinai Immunotherapeutics NASDAQ:SCNI$0.27 -0.01 (-4.83%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$0.26 -0.01 (-4.48%) As of 06/24/2026 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
